<DOC>
	<DOCNO>NCT00001353</DOCNO>
	<brief_summary>This study evaluate safety give lymphocyte ( white blood cell ) contain new gene HIV-infected individual determine long cell survive bloodstream . Although genetically alter cell directly benefit participant , knowledge safety , side effect survival gene-marked cell HIV-infected patient may lead new treatment strategy . Identical twin pair 18 year age older-one infected HIV , non-infected-may eligible study . Candidates screen medical history , physical examination blood test . All participant tetanus booster shot . Non-infected twin undergo procedure call apheresis collect white blood cell . For procedure , whole blood collect needle arm vein , similar donate blood . The blood separate component centrifugation ( spin ) , white cell remove , rest blood return body , either needle another needle arm . The harvested white cell grown culture approximately 10 day 2 week increase number 1000-fold . A gene call NeoR , derive bacteria , inserted cell , gene-marked cell infuse HIV-infected twin . HIV-infected twin admit NIH Clinical Center first cell infusion . The gene-marked cell infused 60-minute period plastic tube ( catheter ) place arm vein , , suitable arm vein find , special catheter place large vein neck chest . Vital sign ( temperature , pulse , blood pressure breathe rate ) , blood oxygen concentration , urine output monitor regularly 24 hour . Blood sample collect infusion monitor gene-marked cell . Patients discharge next day . They return NIH daily first week ( Monday Thursday ) monitor CD4 cell count , plasma viral burden , p24 antigen level , HIV level presence NeoR gene , weekly next 5 week test others monitor blood urine chemistry , blood count immune function marker . If NeoR gene detect first cell infusion , entire procedure ( donor apheresis , gene mark infusion cell ) repeat twice-about every 6 week . If first infusion uncomplicated , second third infusion may do outpatient basis , monitor 6 hour rather 24 . Six week third infusion , test schedule monthly 6 month yearly long-term follow-up . In addition procedure , patient baseline CD4 lymphocyte count le 100 cell per cubic millimeter blood ask undergo apheresis periodically obtain accurate result determine long NeoR gene persist blood . The procedure do weekly first 6 week infusion cell , week 8 , every 4 week gene longer detect lymphocyte . The schedule may change , require frequent apheresis .</brief_summary>
	<brief_title>Safety Survival Genetically Modified White Blood Cells HIV-Infected Persons - A Study Identical Twin Pairs</brief_title>
	<detailed_description>This phase I/II pilot project evaluate survival , tolerance , safety , efficacy infusion activate , gene mark , syngeneic T lymphocyte obtain HIV seronegative identical twin functional immune status HIV infect twin recipient . T cell seronegative twin obtain periodic apheresis , induce polyclonal proliferation anti-CD3 rIL-2 stimulation , transduce distinctive neoR retroviral vector , expand 10-1,000 fold number approximately 2 week culture . These mark T cell infuse seropositive twin survival uniquely mark T cell population monitor vector-specific PCR , recipient ' functional immune status monitor standard vitro vivo test protocol . A total 3 cycle treatment may give interval 6 week infusion .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>An identical twin pair , one seropositive HIV , twin seronegative , standard ELISA Western blot test . Patients Kaposi 's sarcoma eligible study , must receive systemic therapy KS within 4 week prior entry . The diagnosis KS must confirm biopsy . Patients must free serious psychological emotional illness able provide write informed consent . Anticipated survival great 3 month . 18 year age old . Treatment FDAapproved and/or expand access antiretroviral agent ( ) patient baseline CD4 count 500 cells/mm3 . Patients baseline CD4 count 500 cells/mm3 eligible receive cell therapy protocol , must treat antiretroviral therapy evidence significant persistent viral activation occur association cell infusion ( 50 percent great increase baseline virologic parameter least 2 consecutive week ) . No patient lymphoma . Willing comply current NIH Clinical Center guideline concern appropriate notification current sexual partner individual regard HIV positive serostatus risk transmission HIV infection . No recent history substance abuse unless evidence provide ongoing therapeutic intervention ( i.e. , medical therapy counseling ) control abuse . No pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2002</verification_date>
	<keyword>AIDS</keyword>
	<keyword>Immune Based Therapy</keyword>
	<keyword>Adoptive Immunotherapy</keyword>
	<keyword>Lymphapheresis</keyword>
	<keyword>Ex Vivo Activation</keyword>
	<keyword>HIV</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Indinavir</keyword>
</DOC>